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administrative censoring, and data generating models. Combining the findings 
from our review and our simulation study, we made practical recommendations on 
the use of adjustment methods in HTA. Results: Our review demonstrates that 
adjustment methods make important limiting assumptions. Our simulation stud-
ies show that the bias associated with alternative methods is highly associated 
with deviations from their assumptions. Our recommended analysis framework 
aims to help researchers find suitable adjustment methods on a case-by-case 
basis. The characteristics of clinical trials and the treatment switching mechanism 
observed within them, should be considered alongside the key assumptions of the 
adjustment methods. ConClusions: The limitations associated with switching 
adjustment methods mean that different methods are appropriate in different 
scenarios. In some scenarios all methods may be prone to important bias. The data 
requirements of adjustment methods have important implications for people who 
design and analyse trials which allow treatment switching.
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objeCtives: Decision makers often rely on health economic models populated 
with clinical trial data to inform initial assessments about treatment selection, 
coverage, and reimbursement. To date, there have been few (if any) published model 
re-analyses using real-world evidence (RWE). The purpose of this study is to 1) assess 
real-world health and economic outcomes associated with oral anticoagulant vs. 
low molecular weight heparin (LMWH) as prophylaxis for venous thromboembo-
lism (VTE) in patients undergoing total hip (THR) or knee (TKR) replacement, and 2) 
compare results of a health economic model populated with clinical trial data vs. 
RWE. Methods: Patients who underwent THR or TKR between July 2011 and June 
2012 were identified in a US commercial insurance claims database. Patients were 
required to be continuously enrolled 3 months pre-/post-index and were excluded if 
treated with multiple anti-coagulants within 10 days post-index. A propensity score 
matching technique was employed to reduce selection bias. Patient characteristics, 
inpatient-related VTE events and health care costs were determined. A health eco-
nomic model previously parameterized with clinical trial data was repopulated and 
reanalyzed using inputs derived from the claims study. Results: A total of 14,880 
patients were identified (7,440 oral anticoagulant, 7,440 LMWH). In both groups, 
mean age was 59 and 53% were female. Compared with LMWH, oral anticoagulant 
use was associated with fewer symptomatic VTE events over 1-year. When repopu-
lated with clinical inputs from claims data, the model projected similar VTE event 
differences as trial-based model (-0.023 vs. -0.015). Costs (per patient/year) in oral 
anticoagulant and LMWH groups were consistent across the trial-based model ($385 
vs. $1,011), claims-based model ($437 vs. $1,290), and direct reported results from 
claims analysis ($506 vs. $1,125). ConClusions: Use of RWE is a practical and 
objective way to validate a trial-based health economic model. Future work should 
consider study design issues and practical use of results.
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objeCtives: We developed an individual-based micro-simulation model for radio-
therapy treatment in non small-cell lung cancer (NSCLC). The aim was to explore 
the suitability of multi-state statistical modelling in heath economics, as a tool to 
parameterize a simulation model that tracks clinical events over time, taking patient 
and tumour features into account. Methods: The model contains the four clinical 
states ‘A: alive without local recurrence (LR) or metastasis (M)’, ‘LR’, ‘M’, and ‘Death’. 
Transition rates were estimated using multi-state statistical modelling, a technique 
that allows the simultaneous estimation of hazards for multiple transitions, taking 
covariates as well as the occurrence and timing of previous events into account. Each 
of the hazards from A to either LR, M and Death were adjusted for the presence of the 
other competing risks. Individual patients were simulated by repeatedly sampling 
a patient profile, consisting of patient and tumour characteristics. Subsequently, for 
each patient a pathway through the model was simulated. The internal validity of 
the model was verified by comparing intermediate simulation outcomes and overall 
survival under two different radiotherapy strategies to the original data used for 
estimation. Finally, the model was externally validated by comparing model outcomes 
to Dutch cancer registry data. Results: Model simulations for the two radiotherapy 
strategies demonstrated internal validity, with predicted probabilities for the occur-
rence of LRs, Ms, deaths, and the occurrence of toxicities within 3 years that fell within 
the 95% confidence intervals of the data. The same was observed for the prediction 
of overall survival. Comparison of the model predictions to the Dutch cancer registry 
data showed a moderate fit. ConClusions: Multi-state statistical modelling is a 
useful technique for obtaining the transition rates that are required for the quantifi-
cation of a micro-simulation model. In future, our model will be used to evaluate the 
cost-effectiveness of individualized treatment strategies.
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we illustrate how this approach may be developed to a) simultaneously and system-
atically compare health economic outcomes predicted by multiple Markov models; 
b) address the question of whether (and how) to weight different models within an 
ensemble based on different performance metrics and model skill scores; c) identify, 
quantify, and partition total uncertainty across a multi-model ensemble into different 
sources (for example, to highlight where future research priorities may optimally lie to 
further improve the robustness of policy recommendations through model improve-
ment and data collection); and d) apply this approach to some real-world examples.
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objeCtives: Qualitative interviews, as tools for scientific evidence generation, are 
often excluded from consideration in health outcomes research. Lack of methodologi-
cal rigour and the non-reproducibility and non-generalizability of results are often 
used to justify quantitative methodologies. Here we present an illustrative exam-
ple of qualitative interviewing’s value within health outcomes research. In a study 
aiming to measure patient and physician preferences for hepatitis C treatments, a 
discrete choice experiment was designed and a systematic literature review was 
conducted. Methods: To assess the comprehensibility and relevance of the ques-
tionnaire as well as to estimate the value and preciseness of assumptions, pre-tests 
consisting of a questionnaire pilot followed by a semi-direct interview were con-
ducted. The semi-direct interviewing followed rigorous methods, including defined 
themes assembled in a discussion guide and behavioural rules for the interviewer 
to promote axiological neutrality. Analytical methods using predefined codes for 
the interpretation enabled a systematic understanding of datasets. Results: The 
qualitative component mostly validated but sometimes challenged the theoretical 
assumptions of the discrete-choice experiment, which had been previously developed 
on the basis of the systematic literature review. Interviews shed light on occasional 
complexity and lack of comprehensibility of some questions. The qualitative analysis 
provided insights to patients’ and physicians’ experience of their treatment selection 
process. It included socio-psychological dispositions, like the aversion for work absen-
teeism or the importance of social representation encouraging patients to prefer treat-
ments which side effects would not affect their social capacities. ConClusions: This 
method provided in-depth and structured feedback from a small group of patients and 
physicians. As health outcomes studies increasingly require to expand their level of 
detail and sensitivity by entering subjective fields of personal preferences, patients’ 
experiences and decision-making processes, there is a pressing need for conduct-
ing qualitative micro-level studies prior to supporting broader, field-based studies.
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Patient preference-based health-related quality of life measures (utilities) are a criti-
cal input in cost-effectiveness analyses of pharmaceuticals and other health care 
technologies. Over recent years it has become more common for utility data to be 
collected alongside key clinical data within the pivotal Phase III trials. However, utility 
data are often not available for all patients throughout the entire course of the trial. 
The authors discuss the concept that there are unique characteristics of utility data 
that need to be considered when dealing with missing values, including the large 
inter-patient variability typically present at baseline. Missing data arise because i) 
patients become more ill and are less able to complete patient-reported instruments, 
ii) patients die during the course of the trial, or iii) patients are censored at later stages 
of the trial due to rolling recruitment. Whilst this is often a problem in oncology trials, 
it is also a consideration in other interventional and observational research designed 
to inform pharmacoeconomic evaluations. Situations where individual patient data 
are accessible and where only summary statistics are available are discussed. The 
practical considerations of how such re-analysed data should then be included within 
an economic model are discussed, given the manner in which utilities are incorpo-
rated will vary depending on the nature of the health states used.
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objeCtives: Treatment switching is a common issue in clinical trials of cancer 
treatments – often patients randomised to the control group are permitted to 
switch onto the experimental treatment at some point during follow-up. In such 
circumstances an intention to treat (ITT) analysis will result in biased estimates 
of the overall survival advantage – and therefore the cost-effectiveness – associ-
ated with the experimental treatment. Methods to adjust for switching have been 
used inconsistently and potentially inappropriately in health technology assess-
ments (HTA). We present an analytical framework to guide analysts on the use 
of methods to adjust for treatment switching in the context of economic evalua-
tions. Methods: We conducted a review of methods used to adjust for treatment 
switching in HTA, and two rigorous simulation studies to assess the performance 
of adjustment methods in a range of realistic scenarios. We tested different simu-
lated trial sample sizes, crossover proportions, treatment effect sizes, levels of 
